HIV

Gilead and Merck to collaborate on long-acting HIV treatments

By
1 Mins read
212
0
Share
Reading Time: < 1 minute

The companies have agreed to jointly develop and commercialise long-acting, investigational treatment combinations of lenacapavir and islatravir for HIV.  Read More

212
0
Share
Related posts
HIV

HIV funding fell by $2bn last year in wake of Trump’s aid cuts

By
1 Mins read
Reading Time: < 1 minuteFunding for HIV responses in low- and middle-income countries fell by $2.1 billion (£1.6bn) last year after the Trump administration made substantial…
HIV

HIV, pregnancy, violence: The three-pronged crisis stealing the future of Africa's girls

By
1 Mins read
Reading Time: < 1 minuteMs Abigael* is not just a statistic. She is a young woman navigating three immediate threats to her life:  the risk of…
HIV

Zambia Must Decide Today: Open Minerals To American Firms Or Lose HIV Support For 1.3 Million

By
1 Mins read
Reading Time: < 1 minuteZambia must choose between granting US mineral access or losing crucial HIV treatment funding. Read More
Subscribe to our Blog

Let's stay in touch. Subscribe to our blog and get our best content in your inbox. 

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.